Bio-Techne Corp at Stifel Healthcare Conference Transcript

Nov 15, 2022 / 07:25PM GMT
Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division - MD & Senior Analyst

Okay. Welcome, everybody. We're back on the Life Sciences and Diagnostics track at the Stifel Healthcare Conference. Happy to have Bio-Techne with us. Jim Hippel, CFO; Kim Kelderman, from Diagnostics and Genomics Group. Thanks, guys, very much for being with us today. A lot to talk about as is usually the case with these things. We're 1 quarter into fiscal '23, but I thought maybe a good idea would be to just sort of look back at fiscal '22 as a starting point. 17% organic growth that came off of a 22% COVID rebound year.

Questions and Answers:

Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division - MD & Senior Analyst

Maybe you can just talk a little bit about the business and what's driving growth right now as we hopefully continue to exit this pandemic period.

James T. Hippel - Bio-Techne Corporation - Executive VP of Finance & CFO

Yes, sure. I mean I'll
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot